These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 9028553)

  • 21. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.
    Humar A; O'Rourke K; Lipton J; Messner H; Meharchand J; Mahony J; Walker I; Wasi P; McGeer A; Moussa G; Chua R; Mazzulli T
    Bone Marrow Transplant; 1999 Jan; 23(1):45-51. PubMed ID: 10037050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
    Parody R; Martino R; Rovira M; Vazquez L; Vázquez MJ; de la Cámara R; Blazquez C; Fernández-Avilés F; Carreras E; Salavert M; Jarque I; Martín C; Martínez F; López J; Torres A; Sierra J; Sanz GF;
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):734-48. PubMed ID: 16785063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease.
    Krause H; Hebart H; Jahn G; Müller CA; Einsele H
    Bone Marrow Transplant; 1997 Jun; 19(11):1111-6. PubMed ID: 9193754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
    Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
    Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
    Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan.
    Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kato S; Kasahara S; Iseki T; Yamaguchi T; Tojo A; Asano S
    Eur J Haematol; 2008 Mar; 80(3):251-7. PubMed ID: 18081702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation.
    Stocchi R; Szydlo R; Craddock C; Kanfer E; Apperley JF; Goldman JM; Ward KN
    Bone Marrow Transplant; 1999 Apr; 23(7):705-9. PubMed ID: 10218848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
    Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
    Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of chronic graft-versus-host disease after unrelated-donor bone marrow transplantation. Kanazawa University Bone Marrow Transplant Team].
    Takami A; Nakao S; Ueda M; Takamatsu H; Sugimori N; Yamazaki H; Miura H; Ito K; Yamaguchi M; Niki T
    Rinsho Ketsueki; 1995 Jan; 36(1):6-11. PubMed ID: 7715080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB; Lichtiger B
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fulminant, CMV-associated, haemophagocytic syndrome following unrelated bone marrow transplantation.
    Sato M; Matsushima T; Takada S; Hatsumi N; Kim K; Sakuraya M; Saito T; Tamura J; Karasawa M; Murakami H; Naruse T
    Bone Marrow Transplant; 1998 Dec; 22(12):1219-22. PubMed ID: 9894728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of cytomegalovirus infection with human leukocyte antigen genotypes in recipients after allogeneic liver transplantation.
    Fan J; Meng XQ; Yang MF; Zhou L; Chen XM; Hu MJ; Fan WW; Ma WH; Li LJ
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):34-8. PubMed ID: 16481279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation.
    Choi JH; Kim DW; Cho SG; Yoo JH; Jeong DC; Han CW; Shin WS; Min WS; Kim HK; Kim CC; Kim DJ
    Bone Marrow Transplant; 1997 Jan; 19(2):187-90. PubMed ID: 9116619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients.
    Humar A; St Louis P; Mazzulli T; McGeer A; Lipton J; Messner H; MacDonald KS
    J Infect Dis; 1999 Feb; 179(2):484-8. PubMed ID: 9878035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT.
    Solano C; Martinez C; Brunet S; Tomás JF; Urbano-Ispizua A; Zuazu J; Ojeda E; Bargay J; Moraleda JM; Bailen A; Sierra J; García-Conde J; Rozman C
    Bone Marrow Transplant; 1998 Dec; 22(12):1129-35. PubMed ID: 9894714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied NJ; Camara R; Mandelli F; Kho P; Kennedy L; Bell AR
    Bone Marrow Transplant; 1997 Jan; 19(2):129-33. PubMed ID: 9116609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.